Camille Carroll
0000-0001-7472-953X
4 papers found
Refreshing results…
Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson’s disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The ‘Exenatide-PD3’ study
Ensuring that COVID-19 research is inclusive: guidance from the NIHR INCLUDE project
Early Detection of Alzheimer's Disease with Blood Plasma Proteins using Support Vector Machines
Simvastatin as a neuroprotective treatment for Parkinson’s disease (PD STAT): protocol for a double-blind, randomised, placebo-controlled futility study
Missing publications? Search for publications with a matching author name.